Alternatives to Oak

A high-disclosure program with clean async onboarding and both molecules nationwide — you pay more, but the price and the process are legible.

The price-first partner: some of the lowest flat, all-inclusive compounded pricing we track, nationwide and async — strong if the monthly number is your deciding factor and you read the annual-prepay fine print.

The budget speed-play: a low entry price on compounded semaglutide, an app-based async intake, and same-week dispatch in all 50 states. The catch is a tiered plan that steps up as you titrate.

The familiar app-first pick, via its Hers side: a fast, polished async funnel and a flat, posted semaglutide price — dependable, if you can tune out the catalog of everything-else it wants to sell you.

A flat $179 for either molecule with a genuinely gentle microdosing tier — a reasonable, all-doses-included partner if you can live with a yearly plan and a pharmacy it doesn't name.

The clinician-forward option: flat pricing on both molecules and a program built around provider check-ins. You pay up and wait a touch longer for a more supervised, hand-held start.

A tidy, flat-priced compounded program — semaglutide from $99, tirzepatide from $169, same price at every dose — from a young, LegitScript-listed brand that keeps its state list and visit format behind the quiz.

The habit-plus-medication route: Noom bolts a prescriber onto its behavior-change app and will chase brand-name coverage through insurance. Powerful if you want coaching, but the true monthly is hard to pin down before you're in.

The async, needle-optional value play: oral or injectable semaglutide and tirzepatide from a low starting price, no video visit, ~3 days to a script — listed with its February 2026 FDA warning letter in plain view.